Trillium Therapeutics Inc (TRIL.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:TRIL
TRIL.CA Key Statistics, Chart & Performance
The current stock price of TRIL.CA is 23.33 null. In the past month the price increased by 5.33%.
TRIL.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TRIL.CA. When comparing the yearly performance of all stocks, TRIL.CA is one of the better performing stocks in the market, outperforming 93.21% of all stocks.
TRIL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRIL.CA. No worries on liquidiy or solvency for TRIL.CA as it has an excellent financial health rating, but there are worries on the profitability.
TRIL.CA Financial Highlights
Over the last trailing twelve months TRIL.CA reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 52.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -139737.5% | ||
| ROA | -21.06% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TRIL.CA Forecast & Estimates
10 analysts have analysed TRIL.CA and the average price target is 18.87 null. This implies a price decrease of -19.12% is expected in the next year compared to the current price of 23.33.
For the next year, analysts expect an EPS growth of -9.05% and a revenue growth -96.9% for TRIL.CA
TRIL.CA Ownership
TRIL.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 608.306M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 390.366M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 137.484M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 71.733M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.19 | 45.021M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| RVX | RESVERLOGIX CORP | N/A | 30.171M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.964M | ||
| MPH | MEDICURE INC | N/A | 12.006M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.678M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About TRIL.CA
Company Profile
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
Company Info
Trillium Therapeutics Inc
2488 Dunwin Drive
Mississauga ONTARIO 02140 CA
CEO: Jan Skvarka
Employees: 33
Phone: 14165950627.0
Trillium Therapeutics Inc / TRIL.CA FAQ
What does Trillium Therapeutics Inc do?
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
Can you provide the latest stock price for Trillium Therapeutics Inc?
The current stock price of TRIL.CA is 23.33 null. The price increased by 0.47% in the last trading session.
What is the dividend status of Trillium Therapeutics Inc?
TRIL.CA does not pay a dividend.
What is the ChartMill rating of Trillium Therapeutics Inc stock?
TRIL.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy TRIL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TRIL.CA.
What is the market capitalization of TRIL stock?
Trillium Therapeutics Inc (TRIL.CA) has a market capitalization of 2.45B null. This makes TRIL.CA a Mid Cap stock.
What is the ownership structure of Trillium Therapeutics Inc (TRIL.CA)?
You can find the ownership structure of Trillium Therapeutics Inc (TRIL.CA) on the Ownership tab.